Nuvilex (NASDAQ:PMCB) Trading Down 3.3% – Should You Sell?

Nuvilex Inc. (NASDAQ:PMCB)’s share price dropped 3.3% during mid-day trading on Wednesday . The company traded as low as $0.76 and last traded at $0.76. Approximately 79,050 shares were traded during trading, a decline of 74% from the average daily volume of 298,982 shares. The stock had previously closed at $0.7856.

Wall Street Analyst Weigh In

PMCB has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Nuvilex in a report on Tuesday, April 21st. Wall Street Zen raised shares of Nuvilex to a “sell” rating in a report on Saturday, January 31st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Nuvilex Price Performance

The stock’s fifty day moving average is $0.74 and its 200-day moving average is $0.78. The stock has a market cap of $8.96 million, a PE ratio of -0.75 and a beta of 0.46.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.